DE69623840D1 - Zusammensetzung zur Hemmung der Thromboseentstehung - Google Patents

Zusammensetzung zur Hemmung der Thromboseentstehung

Info

Publication number
DE69623840D1
DE69623840D1 DE69623840T DE69623840T DE69623840D1 DE 69623840 D1 DE69623840 D1 DE 69623840D1 DE 69623840 T DE69623840 T DE 69623840T DE 69623840 T DE69623840 T DE 69623840T DE 69623840 D1 DE69623840 D1 DE 69623840D1
Authority
DE
Germany
Prior art keywords
thrombosis
clot
thrombin
compositions
thrombus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69623840T
Other languages
English (en)
Inventor
Jeffrey I Weitz
Jack Hirsh
Edward Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hamilton Civic Hospitals Research Development Inc
Original Assignee
Hamilton Civic Hospitals Research Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/540,324 external-priority patent/US5744457A/en
Application filed by Hamilton Civic Hospitals Research Development Inc filed Critical Hamilton Civic Hospitals Research Development Inc
Application granted granted Critical
Publication of DE69623840D1 publication Critical patent/DE69623840D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
DE69623840T 1995-03-31 1996-04-01 Zusammensetzung zur Hemmung der Thromboseentstehung Expired - Lifetime DE69623840D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41233295A 1995-03-31 1995-03-31
US48587295A 1995-06-07 1995-06-07
US08/540,324 US5744457A (en) 1995-03-31 1995-10-06 Compositions and methods for inhibiting thrombogenesis

Publications (1)

Publication Number Publication Date
DE69623840D1 true DE69623840D1 (de) 2002-10-31

Family

ID=27410936

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69623840T Expired - Lifetime DE69623840D1 (de) 1995-03-31 1996-04-01 Zusammensetzung zur Hemmung der Thromboseentstehung

Country Status (4)

Country Link
EP (1) EP0735050B1 (de)
AT (1) ATE224918T1 (de)
DE (1) DE69623840D1 (de)
GB (1) GB2299998B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
EP0986581A1 (de) * 1997-06-06 2000-03-22 Hamilton Civic Hospitals Research Development, Inc. Modifiziertes, niedermolekulares heparin, das gerinnselzugehörige gerinnungsfaktoren verhindert
AR022909A1 (es) * 1999-03-11 2002-09-04 Du Pont Pharm Co Sinergia entre heparina de bajo peso molecular e inhibidores de la agregacion plaquetaria, que provee una terapia combinada para la prevencion ytratamiento de diversas afecciones tromboembolicas
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
JP2002538226A (ja) * 1999-03-11 2002-11-12 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤およびアスピリン、組織プラスミノーゲンアクチベータ（ＴＰＡ）、ＧＰＩＩｂ／ＩＩＩａ拮抗剤、低分子量ヘパリンまたはヘパリンの組合せ使用による血栓症の治療
EP2402753A1 (de) 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analyse von sulfatierten Polysacchariden
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2207811B1 (de) * 2007-11-02 2017-01-04 Momenta Pharmaceuticals, Inc. Nicht gerinnungshemmende polysaccharidzusammensetzungen
WO2009059284A2 (en) * 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
JP5982361B2 (ja) 2010-04-16 2016-08-31 モメンタ ファーマシューティカルズ インコーポレイテッド 組織標的化方法
JP5905455B2 (ja) 2010-06-17 2016-04-20 モメンタ ファーマシューティカルズ インコーポレイテッド 発毛を促進する方法および組成物
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
RU2617764C2 (ru) * 2011-12-19 2017-04-26 Дилафор Аб Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение
EP3003324A4 (de) 2013-05-28 2017-01-25 Momenta Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen
EP3003323A4 (de) * 2013-05-28 2016-12-28 Momenta Pharmaceuticals Inc Polysaccharidzusammensetzungen und zugehörige verfahren
GB2515315A (en) * 2013-06-19 2014-12-24 Dilafor Ab New Processes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
US4916219A (en) * 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
ATE84217T1 (de) * 1988-08-24 1993-01-15 Akzo Nv Fragmente und fraktionen von heparin mit wirkung gegen hiv.
SE9002550D0 (sv) * 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
FR2687158B1 (fr) * 1992-02-07 1995-06-30 Rhone Poulenc Rorer Sa Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation.

Also Published As

Publication number Publication date
EP0735050A3 (de) 1997-01-22
GB2299998B (en) 1997-03-26
GB2299998A (en) 1996-10-23
EP0735050B1 (de) 2002-09-25
ATE224918T1 (de) 2002-10-15
EP0735050A2 (de) 1996-10-02
GB9606881D0 (en) 1996-06-05

Similar Documents

Publication Publication Date Title
DE69623840D1 (de) Zusammensetzung zur Hemmung der Thromboseentstehung
WO1996029973A3 (en) Compositions and methods for inhibiting thrombogenesis
CA1136620A (en) Heparin fragments having selective anticoagulation activity
Lijnen et al. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
Wallén et al. Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin
AU596951B2 (en) Blood coagulation inhibiting proteins, processes for preparing them and their uses
AU642626B2 (en) Novel heparin derivatives and process for the preparation thereof
Haverkate et al. Anticlotting properties of fragments D from human fibrinogen and fibrin
JPS60135401A (ja) デキストラン誘導体
BR0012202A (pt) Composições de heparina de peso molecular médio (mmwh), método de tratamento de uma condição trombótica, método de prevenção da formação de um trombo, método de inibição da formação de trombos, composição farmacêutica, método de tratamento de trombose venosa profunda, método de prevenção de embolia pulmonar, método de preparação e usos de uma composição de mmwh
IT1230582B (it) Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
Gibbs et al. Isolation and anticoagulant properties of polysaccharides of Typha Augustata and Daemonorops species
US4672030A (en) Test kit for the determination of activated thromboplastin time (PTT) with increased sensitivity to heparin
Hatton et al. On the interaction of rabbit antithrombin III with the luminal surface of the normal and deendothelialized rabbit thoracic aorta in vitro
Arnander et al. Thrombin uptake and inhibition on endothelium and surfaces with a stable heparin coating: a comparative in vitro study
Kindness et al. Anticoagulant effects of sulphated polysaccharides in normal and antithrombin III-deficient plasmas.
Budzynski et al. The interference of plasmic degradation products of human crosslinked fibrin with clot formation
Swedenborg et al. Inactivation of thrombin by the aortic endothelium
Patel et al. Covalent antithrombin–heparin complexes
Griffith et al. Fractionation of heparin by affinity chromatography on covalently-bound human α-thrombin
Serra et al. Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions
GB2051103A (en) Heparin fractions
US20010046974A1 (en) Modified low molecular weight heparin that inhibits clot associated coagulation factors
Edgar et al. The effect of temperature on formation of fibrin complexes
Tarvady et al. Effect of heparin on wound healing

Legal Events

Date Code Title Description
8332 No legal effect for de